Vestal Point Capital’s Regenxbio RGNX Stock Holding History

Vestal Point Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-108,525	Closed	-$909K	–	88
2026 Q1	$909K	Buy	108,525 +74,525	+219%	+$783K	0.03%	86
2025 Q4	$490K	Buy	+34,000	New	+$424K	0.02%	75

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vestal Point Capital's RGNX Position: Q2 2026 in Review

Vestal Point Capital sold out of Regenxbio (RGNX) in Q2 2026, closing a stake of 108,525 shares — an estimated $909K sold.

Vestal Point Capital first reported a position in RGNX in Q4 2025 and held it in 2 quarters. The position peaked at $909K in Q1 2026. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Vestal Point Capital reported no remaining Regenxbio position as of Q2 2026 after selling out during the quarter.
Vestal Point Capital sold 108,525 Regenxbio shares in Q2 2026, an estimated $909K.
Vestal Point Capital first reported a position in Regenxbio in Q4 2025 and held it in 2 quarters.
Vestal Point Capital's Regenxbio position peaked at $909K in Q1 2026.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.